Merck inks deal with Xian Janssen for type 2 diabetes drug
Global drug giant, Merck has signed an agreement with China’s Xian Janssen Pharmaceuticals in Beijing recently, to launch type 2 diabetes drug INVOKANA (canagliflozin) in China.
Through this agreement, the two companies will work closely together on future development, distribution, promotion, access, marketing and sales of INVOKANA in the country and Merck will hold the exclusive rights for INVOKANA’s promotion in China.
INVOKANA is a member of a novel class of drugs known as sodium-glucose co-transporter 2 (SGLT-2) inhibitor and was approved in China in September 2017. INVOKANA is approved for treatment of type 2 diabetes in combination with metformin or with metformin plus sulfonylurea in adults who have not achieved adequate glycaemic control on these oral therapies.